6549 studies found for:    delta-24
Show Display Options
Rank Status Study
1 Completed Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Procedure: Tenckhoff Catheter placement;   Drug: Ad5-delta24RGD
2 Completed Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma
Conditions: Brain Tumor;   Recurring Glioblastoma
Intervention: Biological: delta-24-RGD adenovirus
3 Completed DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Conditions: Brain Cancer;   Central Nervous System Diseases
Interventions: Drug: DNX-2401;   Procedure: Tumor Removal
4 Recruiting Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
Conditions: Glioblastoma Multiforme;   Recurrent Tumor
Intervention: Procedure: DNX2401 and Temozolomide
5 Recruiting DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Single intratumoral injection of DNX-2401;   Drug: interferon gamma
6 Unknown  Application of Contrast Enhance Ultrasound to Evaluate Hemodynamics Change in MCA With Moderate to Severe Stenosis
Condition: Stenosis
Intervention: Drug: atorvastatin
7 Not yet recruiting ASIS for Botox in Upper Limb Spasticity
Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke;   Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12,;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
8 Not yet recruiting ASIS for Botox in Cervical Dystonia
Conditions: Cervical Dystonia Adults ,;   Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
9 Unknown  Minimal Change Esophagitis by i-Scan Endoscopy in Dyspeptic Patients
Condition: Gastroesophageal Reflux Disease
Intervention: Procedure: Endoscopy
10 Recruiting RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
Condition: Multiple Sclerosis
Intervention: Drug: Rebif®
11 Not yet recruiting ASIS for Botox in Chronic Migraine
Condition: Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24,;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
12 Recruiting Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density
Condition: HIV-1 Infection
Interventions: Drug: Dolutegravir, 50mg every 24 hours;   Drug: Protease Inhibitor/ritonavir
13 Completed
Has Results
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide;   Drug: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
14 Completed
Has Results
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
Condition: Schizophrenia
Intervention: Drug: Paliperidone
15 Terminated
Has Results
Dynepo Infrequent Dosing Study
Conditions: Anemia;   Kidney Failure
Interventions: Drug: Dynepo (Epoetin delta);   Drug: Dynepo
16 Completed Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants
Condition: Procedural Pain
Interventions: Drug: sucrose 24% oral solution;   Drug: sterile water
17 Terminated
Has Results
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
Conditions: Leukemia;   Lymphoma;   Malnutrition;   Myelodysplastic Syndromes;   Unspecified Childhood Solid Tumor, Protocol Specific;   Weight Changes
Interventions: Dietary Supplement: Ensure;   Dietary Supplement: PediaSure;   Drug: cyproheptadine hydrochloride
18 Completed Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Condition: Healthy Male Adults
Interventions: Drug: 8IU intranasal oxytocin;   Drug: 24 IU intranasal oxytocin;   Drug: 1 IU intravenous oxytocin;   Drug: Placebo
19 Completed Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease
Conditions: Diabetes Mellitus;   Essential Hypertension;   Renal Failure;   Chronic Nephropathy
Intervention: Device: Ambulatory blood pressure monitoring
20 Terminated
Has Results
The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
Condition: Back Pain
Interventions: Drug: Parathyroid hormone (PTH) (1-84);   Drug: Alendronate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years